NASDAQ:BTAI

BioXcel Therapeutics - BTAI Stock Forecast, Price & News

$11.82

+0.48 (+4.23%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $11.22
▼
$12.05
50-Day Range: $11.19
▼
$16.62
52-Week Range: $8.80
▼
$36.49

Volume: 229,505 shs
Average Volume: 204,633 shs
Market Capitalization: $331.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $54.14

BioXcel Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 358.1% Upside
$54.14 Price Target
Short Interest: Bearish
15.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.13
Upright™ Environmental Score
News Sentiment: 1.88
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.13) to ($4.63) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

335th out of 1,095 stocks

Pharmaceutical Preparations Industry

151st out of 547 stocks

3.3

Analyst's Opinion

Consensus Rating
BioXcel Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $54.14, BioXcel Therapeutics has a forecasted upside of 358.1% from its current price of $11.82.
Amount of Analyst Coverage
BioXcel Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
15.04% of the float of BioXcel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
BioXcel Therapeutics has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in BioXcel Therapeutics has recently decreased by 2.39%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
BioXcel Therapeutics does not currently pay a dividend.
Dividend Growth
BioXcel Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.
Environmental Sustainability
The Environmental Impact score for BioXcel Therapeutics is -1.13.

3.3

News and Social Media Coverage

News Sentiment
BioXcel Therapeutics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for BioXcel Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
37.00% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
45.32% of the stock of BioXcel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($5.13) to ($4.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioXcel Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioXcel Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioXcel Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioXcel Therapeutics (NASDAQ:BTAI) Stock

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Stock News Headlines

September 14, 2022 | finance.yahoo.com

BioXcel Therapeutics, Inc. (BTAI)

September 7, 2022 | finance.yahoo.com

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

August 29, 2022 | seekingalpha.com

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

August 18, 2022 | benzinga.com

SERENITY III Trial to Initiate 2H22

August 18, 2022 | nasdaq.com

What Kind Of Investors Own Most Of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)?

August 12, 2022 | finance.yahoo.com

BTAI: SERENITY III Trial to Initiate in 2H22…

August 12, 2022 | investing.com

BioXcel Therapeutics Misses Q2 EPS by 15c

August 9, 2022 | seekingalpha.com

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2022 Results - Earnings Call Transcript

August 9, 2022 | finance.yahoo.com

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

August 9, 2022 | finance.yahoo.com

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

August 3, 2022 | finance.yahoo.com

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference

August 1, 2022 | finance.yahoo.com

BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal

July 26, 2022 | finance.yahoo.com

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 20, 2022 | finance.yahoo.com

Is BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Popular Amongst Institutions?

June 7, 2022 | finance.yahoo.com

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

June 4, 2022 | finance.yahoo.com

2 Stocks Under $20 That Could Double Your Money

May 20, 2022 | finance.yahoo.com

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

May 19, 2022 | finance.yahoo.com

Why Shares of BioXcel Therapeutics Climbed 25.2% This Week

May 10, 2022 | finance.yahoo.com

BTAI: Data from TRANQUILITY II Trial in Late 2022 or Early 2023…

May 9, 2022 | seekingalpha.com

BioXcel stock falls as Q1 net loss widens Y/Y but Igalmi approval positions to "realize" FY22 goals

May 9, 2022 | finance.yahoo.com

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 5, 2022 | finance.yahoo.com

Why BioXcel Therapeutics Shares Went Up 12.9% This Week

May 5, 2022 | finance.yahoo.com

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

May 3, 2022 | finance.yahoo.com

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

April 30, 2022 | finance.yahoo.com

2 Small-Cap Stocks With Monster Upsides, According to Wall Street

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Company Calendar

Last Earnings: 8/09/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BTAI
CUSIP: N/A
CIK: 1720893
Web: www.bioxceltherapeutics.com
Phone: (475) 238-6837
Fax: N/A
Employees: 89
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $54.14
High Stock Price Forecast: $85.00
Low Stock Price Forecast: $19.00
Forecasted Upside/Downside: +358.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -59.15%
Return on Assets: -50.86%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 12.25
Quick Ratio: 12.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.92 per share
Price / Book: 1.49

Miscellaneous

Outstanding Shares: 28,020,000
Free Float: 17,654,000
Market Cap: $331.20 million
Optionable: Not Optionable
Beta: 1.23

Key Executives

Dr. Vimal D. Mehta Ph.D. (Age 61)
Founder, CEO, Pres, & Director
Comp: $1.41M

Dr. Frank D. Yocca Ph.D. (Age 66)
Sr. VP & Chief Scientific Officer
Comp: $452.58k

Mr. Javier Rodriguez (Age 50)
Sr. VP, Chief Legal Officer & Corp. Sec.
Comp: $470.53k

Dr. Krishnan Nandabalan Ph.D. (Age 59)
Chief Digital Officer ?& Director
Comp: $150k

Mr. Richard I. Steinhart MBA (Age 65)
Sr. VP & CFO

Ms. Mary Coleman
VP of Investment Relations

Dr. Iris Francesconi Ph.D.
Sr. VP of Marketing, Market Research & Commercial Assessments

Dr. Vincent J. O'Neill M.D. (Age 53)
B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer

Dr. Cedric Burg
VP and Head of Global Clinical Operations & Project Management

Dr. Chetan D. Lathia Ph.D.
Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTAI Stock - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BTAI shares.
View BTAI analyst ratings or view top-rated stocks.
What is BioXcel Therapeutics' stock price forecast for 2022?: 5 Wall Street research analysts have issued twelve-month price targets for BioXcel Therapeutics' shares. Their BTAI share price forecasts range from $19.00 to $85.00. On average, they expect the company's share price to reach $54.14 in the next twelve months. This suggests a possible upside of 358.1% from the stock's current price.
View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts.
How have BTAI shares performed in 2022?: BioXcel Therapeutics' stock was trading at $20.33 on January 1st, 2022. Since then, BTAI shares have decreased by 41.9% and is now trading at $11.82.
View the best growth stocks for 2022 here.
When is BioXcel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BTAI earnings forecast.
How were BioXcel Therapeutics' earnings last quarter?: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.15. During the same quarter in the previous year, the company earned ($1.11) earnings per share.

What other stocks do shareholders of BioXcel Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).
When did BioXcel Therapeutics IPO?: (BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is BioXcel Therapeutics' stock symbol?: BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."
How do I buy shares of BioXcel Therapeutics?: Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioXcel Therapeutics' stock price today?: One share of BTAI stock can currently be purchased for approximately $11.82.
How much money does BioXcel Therapeutics make?: BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $331.20 million. The company earns $-106,930,000.00 in net income (profit) each year or ($4.36) on an earnings per share basis.
How can I contact BioXcel Therapeutics?: BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.

This page (NASDAQ:BTAI) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioXcel Therapeutics - BTAI Stock Forecast, Price & News

BioXcel Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows